| abstract |
A method and pharmaceutical composition for diagnosing multiple sclerosis (MS) or MS predisposition or risk in an individual and predicting response to MS treatment in an individual. The method analyzes genotyping of MS cases and controls, examines single nucleotide polymorphism (SNP) relationships based on the population, and further performs family linkage analysis using families with high MS prevalence. It was. As a result, 171 SNPs related to anti-TPO antibody, anti-TG antibody, CD-40L, and various cytokine amounts in MS patients were identified. The SNP of the ANO6 gene of Chr12q12 was related to IL-1β and the like, and the SNP of the TPM1 gene of Chr15q22.2 was related to IL-4. The above antibodies, cytokines and SNPs serve as markers for MS diagnosis and treatment response. [Selection] Figure 3 |